Welcome, Guest. Please login or register.
April 07, 2020, 09:50:00 am

Login with username, password and session length


Members
  • Total Members: 6203
  • Latest: Jgrace
Stats
  • Total Posts: 54824
  • Total Topics: 4729
  • Online Today: 71
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 1
Guests: 53
Total: 54

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Case report of intravenous milkthistle as antiviral in HCV/HIV coinfection  (Read 5834 times)

0 Members and 2 Guests are viewing this topic.

Offline Electric Sheep

  • Newbie
  • Posts: 2
Found this paper when searching for milkthistle's effects at reducing immune activation (through its NF-kB inhibition) - Although as it turns out it works via affecting glucose metabolism as well:

Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV–HCV coinfected patient
www.ncbi.nlm.nih.gov/pubmed/20709593
Quote
Results: After 2 weeks of ivSIL therapy both HCV-RNA and HIV-RNA become undetectable. On ivSIL monotherapy we noticed a trend towards an increase of CD4+ cell counts and a decrease of HIV-RNA. After 16 weeks PEGIFN + RBV was discontinued due to patients wish because of adverse events. HCV-RNA was still negative 24 weeks after cessation of therapy, while HIV-RNA returned to baseline levels.

Offline lporterrn

  • Member
  • Posts: 1,984
  • LucindaPorterRN
    • LucindaPorterRN
Re: Case report of intravenous milkthistle as antiviral in HCV/HIV coinfection
« Reply #1 on: February 12, 2015, 02:50:24 pm »
The problem with milk thistle is that we can't get pharmaceutical grade in the U.S., and what is commercially available is over non-therapeutic. Sigh...I stopped buying it.
Lucinda Porter, RN
1988 Contracted HCV
1997 Interferon nonresponder
2003 PEG + ribavirin responder-relapser
2013 Cured (Harvoni + ribavirin clinical trial)
http://blogs.hepmag.com/lucindakporter/

Offline Electric Sheep

  • Newbie
  • Posts: 2
Re: Case report of intravenous milkthistle as antiviral in HCV/HIV coinfection
« Reply #2 on: February 12, 2015, 06:25:05 pm »
Do you mean the concentration of active ingredient(s) is low? I didn't quite understand
I think when the injectable formulation is made from extract it'll be restandardized to a new concentration anyway, so low/variable strength milkthistle could also be used as raw material

Offline lporterrn

  • Member
  • Posts: 1,984
  • LucindaPorterRN
    • LucindaPorterRN
Re: Case report of intravenous milkthistle as antiviral in HCV/HIV coinfection
« Reply #3 on: February 12, 2015, 08:41:52 pm »
Oh - I wasn't commenting on the study milk thistle - they use great ingredients. It is just that some of us read those studies and run out and get milk thistle, not realizing that the active ingredients are low and sometimes non-existent
Lucinda Porter, RN
1988 Contracted HCV
1997 Interferon nonresponder
2003 PEG + ribavirin responder-relapser
2013 Cured (Harvoni + ribavirin clinical trial)
http://blogs.hepmag.com/lucindakporter/

Offline BubbaT

  • Member
  • Posts: 267
I'm surprised some pharmaceutical co. Are not actively pursuing pharmaceutical grade
Silmarin, surely there is a market for it.

Money drives every product,  what about the IV vitamin c therapy?
Have you read the studies using vitamin c?

Are those therapies available in the U.S.?
Age 57 male
Infected late 70's
Diagnosed 95
1a, 2 prev biopsy 95, 2004
Ct 2007, 2015
Treatment Naive
F4 A3. Fibrosure/ CT 2-5-15. Ammonia 222
VL 2.2 mil.
Started Harvoni  3-3-15. 12weeks, finished 5-26-15
4 week VL undetected
12 week EOT undetected

 


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.